BRAF and colorectal carcinoma: Similar to previous observations in a separate CRC cohort [20], the frequency of KRAS mutation was lower in MSI+ compared to MSI- tumors (P = 0.034; Table 3), while the frequency of TP53 mutation was also considerably lower in MSI+ tumors with wildtype BRAF than in MSI- tumors with wildtype BRAF (P = 0.014).